Return on Assets (ROA)
since 2005
Calculation
Bristol-Myers Squibb Co., ROA, long-term trends, calculation
| ROA | = | 100 | × | Net earnings (loss) attributable to BMS1 | ÷ | Total assets1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | -9.66% | = | 100 | × | (8,948) | ÷ | 92,603) |
| Dec 31, 2023 | 8.43% | = | 100 | × | 8,025) | ÷ | 95,159) |
| Dec 31, 2022 | 6.53% | = | 100 | × | 6,327) | ÷ | 96,820) |
| Dec 31, 2021 | 6.40% | = | 100 | × | 6,994) | ÷ | 109,314) |
| Dec 31, 2020 | -7.61% | = | 100 | × | (9,015) | ÷ | 118,481) |
| Dec 31, 2019 | 2.65% | = | 100 | × | 3,439) | ÷ | 129,944) |
| Dec 31, 2018 | 14.06% | = | 100 | × | 4,920) | ÷ | 34,986) |
| Dec 31, 2017 | 3.00% | = | 100 | × | 1,007) | ÷ | 33,551) |
| Dec 31, 2016 | 13.22% | = | 100 | × | 4,457) | ÷ | 33,707) |
| Dec 31, 2015 | 4.93% | = | 100 | × | 1,565) | ÷ | 31,748) |
| Dec 31, 2014 | 5.94% | = | 100 | × | 2,004) | ÷ | 33,749) |
| Dec 31, 2013 | 6.64% | = | 100 | × | 2,563) | ÷ | 38,592) |
| Dec 31, 2012 | 5.46% | = | 100 | × | 1,960) | ÷ | 35,897) |
| Dec 31, 2011 | 11.25% | = | 100 | × | 3,709) | ÷ | 32,970) |
| Dec 31, 2010 | 9.98% | = | 100 | × | 3,102) | ÷ | 31,076) |
| Dec 31, 2009 | 34.22% | = | 100 | × | 10,612) | ÷ | 31,008) |
| Dec 31, 2008 | 17.76% | = | 100 | × | 5,247) | ÷ | 29,552) |
| Dec 31, 2007 | 8.27% | = | 100 | × | 2,165) | ÷ | 26,172) |
| Dec 31, 2006 | 6.20% | = | 100 | × | 1,585) | ÷ | 25,575) |
| Dec 31, 2005 | 10.66% | = | 100 | × | 3,000) | ÷ | 28,138) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in millions
The analysis of the financial data reveals notable fluctuations in net earnings, total assets, and return on assets (ROA) over the period examined.
- Net Earnings (Loss) Attributable to BMS
- The net earnings exhibit significant volatility. Starting at 3,000 million USD in 2005, the figure declines to 1,585 million USD in 2006, then rises to a peak of 10,612 million USD in 2009. Following this peak, net earnings decline sharply to 1,565 million USD in 2015. After recovering to 4,920 million USD in 2018, the earnings experience extreme fluctuations, including negative earnings of -9,015 million USD in 2020 and -8,948 million USD projected for 2024. Positive rebounds occur intermittently, such as 7,025 million USD in 2021 and 8,025 million USD in 2023, indicating an unstable profitability pattern.
- Total Assets
- Total assets show a general upward trend from 28,138 million USD in 2005 to a peak of 129,944 million USD in 2019. This dramatic increase from 2018 to 2019 suggests significant asset acquisition or revaluation. After 2019, total assets decline gradually to 92,603 million USD projected for 2024, indicating divestitures or asset impairment over recent years.
- Return on Assets (ROA)
- ROA demonstrates a fluctuating pattern that is partly correlated with net earnings. High ROA values, such as 34.22% in 2009 and 17.76% in 2008, coincide with peak earnings years. Conversely, the ROA dips to negative values of -7.61% in 2020 and -9.66% projected in 2024, mirroring periods of net losses. The overall declining trend in ROA, despite periods of recovery, reflects decreasing asset efficiency in generating profits over time.
In summary, the data reveals significant fluctuations and volatility in profitability measures, with pronounced peaks and troughs over the period. Total assets follow a steady increase until a marked peak in 2019, followed by a notable decline, which may influence the company's operational capacity. The variations in ROA correspond closely with net earnings trends, highlighting challenges in sustaining consistent profitability relative to asset base size.
Comparison to Competitors
Bristol-Myers Squibb Co., ROA, long-term trends, comparison to competitors
| Bristol-Myers Squibb Co. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | -9.66% | 3.17% | 4.45% | 5.03% | 13.45% | 0.81% | 7.81% | 14.62% | 3.76% | 11.69% | 6.51% | -2.38% |
| Dec 31, 2023 | 8.43% | 3.61% | 6.91% | 5.64% | 8.19% | 9.12% | 20.98% | 0.34% | 0.94% | 11.95% | 6.07% | 15.92% |
| Dec 31, 2022 | 6.53% | 8.53% | 10.06% | 8.55% | 12.62% | 7.27% | 9.57% | 13.30% | 15.91% | 14.85% | 7.15% | 18.30% |
| Dec 31, 2021 | 6.40% | 7.88% | 9.63% | 7.73% | 11.44% | 9.16% | 11.47% | 12.35% | 12.11% | 31.75% | 8.12% | 17.44% |
| Dec 31, 2020 | -7.61% | 3.07% | 11.54% | 4.79% | 13.28% | 0.18% | 8.41% | 7.72% | 6.23% | 20.47% | 9.23% | 23.07% |
| Dec 31, 2019 | 2.65% | 8.84% | 13.13% | 4.85% | 21.17% | 8.74% | 9.59% | 11.66% | 9.72% | 14.29% | 6.33% | 14.15% |
| Dec 31, 2018 | 14.06% | 9.58% | 12.64% | 5.54% | 7.36% | 8.57% | 10.00% | 7.53% | 7.00% | 20.83% | 5.22% | 33.57% |
| Dec 31, 2017 | 3.00% | 7.50% | 2.48% | 5.34% | -0.45% | 6.58% | 0.83% | 2.72% | 12.40% | 13.67% | 3.93% | 7.43% |
| Dec 31, 2016 | 13.22% | 9.01% | 9.95% | 5.64% | 7.05% | 23.70% | 11.71% | 4.11% | 4.20% | 12.84% | 4.40% | -3.87% |
| Dec 31, 2015 | 4.93% | 9.70% | 9.69% | 6.96% | 6.77% | 34.93% | 11.55% | 4.36% | 4.16% | 11.34% | 4.83% | -22.26% |
| Dec 31, 2014 | 5.94% | 6.44% | 7.47% | 7.02% | 6.43% | 34.91% | 12.45% | 12.12% | 5.40% | 8.99% | 4.42% | -31.63% |
| Dec 31, 2013 | 6.64% | 14.14% | 7.68% | 7.77% | 13.29% | 13.67% | 10.42% | 4.17% | 12.78% | 14.38% | 4.00% | -19.19% |
| Dec 31, 2012 | 5.46% | 19.53% | 8.00% | 7.26% | 11.89% | 12.20% | 8.94% | 5.81% | 7.84% | 36.06% | 4.29% | -3.88% |
| Dec 31, 2011 | 11.25% | — | 7.54% | 7.25% | 12.92% | 16.20% | 8.51% | 5.97% | 5.32% | -16.75% | 4.96% | 1.34% |
| Dec 31, 2010 | 9.98% | — | 10.64% | 8.07% | 16.35% | 25.03% | 12.96% | 0.81% | 4.23% | -9.59% | 4.85% | -43.74% |
| Dec 31, 2009 | 34.22% | — | 11.62% | 5.88% | 15.76% | 27.18% | 12.95% | 11.51% | 4.05% | -9.15% | 3.93% | -32.84% |
| Dec 31, 2008 | 17.76% | — | 11.51% | 7.53% | -7.09% | 28.65% | 15.25% | 16.54% | 7.29% | -12.34% | 4.71% | -46.90% |
| Dec 31, 2007 | 8.27% | — | 9.14% | 7.84% | 11.02% | 27.68% | 13.06% | 6.77% | 7.07% | -11.28% | 3.59% | -65.05% |
| Dec 31, 2006 | 6.20% | — | 8.73% | 8.72% | 12.13% | -29.12% | 15.67% | 9.95% | 16.84% | -17.49% | 0.79% | -22.45% |
| Dec 31, 2005 | 10.66% | — | 12.54% | 9.80% | 8.05% | 21.62% | 17.94% | 10.33% | 6.88% | -22.54% | 5.25% | -37.05% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Bristol-Myers Squibb Co., ROA, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Bristol-Myers Squibb Co. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2024 | -9.66% | 5.30% |
| Dec 31, 2023 | 8.43% | 7.25% |
| Dec 31, 2022 | 6.53% | 10.67% |
| Dec 31, 2021 | 6.40% | 10.42% |
| Dec 31, 2020 | -7.61% | 5.45% |
| Dec 31, 2019 | 2.65% | 9.02% |
| Dec 31, 2018 | 14.06% | 8.97% |
| Dec 31, 2017 | 3.00% | 5.28% |
| Dec 31, 2016 | 13.22% | 8.61% |
| Dec 31, 2015 | 4.93% | 8.93% |
| Dec 31, 2014 | 5.94% | 9.45% |
| Dec 31, 2013 | 6.64% | 9.46% |
| Dec 31, 2012 | 5.46% | 8.30% |
| Dec 31, 2011 | 11.25% | 7.30% |
| Dec 31, 2010 | 9.98% | 7.07% |
| Dec 31, 2009 | 34.22% | 10.02% |
| Dec 31, 2008 | 17.76% | 10.37% |
| Dec 31, 2007 | 8.27% | 8.86% |
| Dec 31, 2006 | 6.20% | 11.91% |
| Dec 31, 2005 | 10.66% | 10.42% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Bristol-Myers Squibb Co., ROA, long-term trends, comparison to industry (health care)
| Bristol-Myers Squibb Co. | Health Care | |
|---|---|---|
| Dec 31, 2024 | -9.66% | 5.25% |
| Dec 31, 2023 | 8.43% | 6.71% |
| Dec 31, 2022 | 6.53% | 8.71% |
| Dec 31, 2021 | 6.40% | 8.70% |
| Dec 31, 2020 | -7.61% | 5.45% |
| Dec 31, 2019 | 2.65% | 7.57% |
| Dec 31, 2018 | 14.06% | 6.72% |
| Dec 31, 2017 | 3.00% | 5.31% |
| Dec 31, 2016 | 13.22% | 7.18% |
| Dec 31, 2015 | 4.93% | 7.54% |
| Dec 31, 2014 | 5.94% | 8.41% |
| Dec 31, 2013 | 6.64% | 8.58% |
| Dec 31, 2012 | 5.46% | 7.94% |
| Dec 31, 2011 | 11.25% | 7.22% |
| Dec 31, 2010 | 9.98% | 7.11% |
| Dec 31, 2009 | 34.22% | 9.45% |
| Dec 31, 2008 | 17.76% | 9.08% |
| Dec 31, 2007 | 8.27% | 8.51% |
| Dec 31, 2006 | 6.20% | 10.37% |
| Dec 31, 2005 | 10.66% | 9.62% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).